In this issue:
DESTINY-Gastric04: second-line T-DXd vs. ramucirumab + paclitaxel in HER2+ gastric/GOJ cancer
FGFR2b expression in gastric/GOJ cancer
MATTERHORN: perioperative durvalumab + FLOT in gastric/GOJ cancer
Multi-organ cancer predisposition genes in gastric cancer
PANOVA-3: tumour treating fields + gemcitabine-nab-paclitaxel in locally advanced pancreatic cancer
NO LIMIT: first-line nivolumab + lowdose ipilimumab in MSI-H gastric/GOJ cancer
Impact of incomplete neoadjuvant chemo(radio)therapy in oesophageal cancer
Outcomes of long-term survivors after oesophagectomy
Preoperative (m)FOLFIRINOX vs. gemcitabine-nab-paclitaxel in resected, localised pancreatic cancer
Chemotherapy timing in resected gastric adenocarcinoma
Please login below to download this issue (PDF)